SCHEMBL183005

SCHEMBL183005

NC(=O)c1ccc(-c2c[c]ccc2-c2ccc(C(N)=O)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 7/20 0.44
▸ MKNK2 Q9HBH9 6/20 0.44
▸ CA12 O43570 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ CA14 Q9ULX7 1/20 0.42
▸ PTGS1 P23219 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ PARP15 Q460N3 1/20 0.39
▸ PARP14 Q460N5 1/20 0.39
▸ PARP10 Q53GL7 1/20 0.39
▸ PARP16 Q8N5Y8 1/20 0.39
▸ PARP11 Q9NR21 1/20 0.39
▸ PARP4 Q9UKK3 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ PARP1 P09874 1/20 0.39
▸ MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL323980 0.78 CA2 (0.53) MKNK1MKNK2CA12CA1CA2
SCHEMBL28264223 0.76 MKNK1 (0.61) MKNK1MKNK2CA12CA1CA2
SCHEMBL2225726 0.74 MKNK1 (0.50) MKNK1MKNK2CA12CA1CA2
SCHEMBL27928718 0.73 MKNK1 (0.58) MKNK1MKNK2CHEK2FYNMAP4K4
SCHEMBL55043 0.73 — —
SCHEMBL1002578 0.72 CA2 (0.67) MKNK1MKNK2CA12CA1CA2
Terephthalamide SCHEMBL7508927 0.72 PARP1 (0.67) CA12CA1CA2CA9CA14
SCHEMBL3870677 0.70 CASP1 (0.46) ALDH1A1PARP1IKBKBCHUKMAP4K4
SCHEMBL4924163 0.70 IKBKB (0.43) MKNK2PTGS1KMT2ACYP3A4CYP2C19
SCHEMBL6880077 0.70 ALDH1A1 (0.41) CA1CA2ALDH1A1KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049502-B1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-04 — — EP claimed
EP-2049502-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2009-04-22 — — EP claimed
WO-2008012326-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-31 — — WO claimed
EP-2049502-B1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-04 — — EP disclosed
EP-2049502-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2009-04-22 — — EP disclosed
WO-2008012326-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-31 — — WO disclosed
Send feedback